The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1401-1406

  Curtis, Jeffrey R ^a,b   Xie, Fenglong ^a   Chen, Lang ^a   Baddley, John W ^a   Beukelman, Timothy ^a   Saag, Kenneth G ^a,b   Spettell, Claire ^c   McMahan, Raechele M ^d   Fernandes, Joaquim ^c   Winthrop, Kevin ^e   Delzell, Elizabeth ^b  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c AETNA   (United States)

^d Aetna Specialty Pharmacy   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SUBSTITUTION; FEMALE; HEALTH BEHAVIOR; HOSPITAL INFECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BACTERIAL INFECTIONS; BIOLOGICAL AGENTS; DATABASES, FACTUAL; DRUG SUBSTITUTION; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 79959790816     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.146365     Document Type: Article

References (27)

1. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;4:CD007848.
2. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J 2009;181:787-96.
3. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41.
4. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71.
5. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:4226-7. (Pubitemid 350262351)
6. Tubach F, Salmon D, Ravaud P, et al.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the threeyear prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
7. Dixon WG, Hyrich KL, Watson KD, et al.; BSRBR Control Centre Consortium;BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
8. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23.
9. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
10. Saag KG, Teng GG, Patkar NM, et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
11. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
12. Dixon WG, Symmons DP, Lunt M, et al.; British Society for Rheumatology Biologics Register Control Centre Consortium;British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56:2896-904. (Pubitemid 47502735)
13. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33. (Pubitemid 46608637)
14. Patkar NM, Curtis JR, Teng GG, et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009;62:321-7;327.e1-7.
15. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol 1976;104:609-20. (Pubitemid 8007913)
16. Cadarette SM, Gagne JJ, Solomon DH, et al. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf 2010;19:2-9.
17. Stürmer T, Schneeweiss S, Brookhart MA, et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005;161:891-8. (Pubitemid 40577844)
18. FRAX. Welcome to FRAX. http://shef.ac.uk/FRAX (accessed 31 May 2008).
19. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. (Pubitemid 28213628)
20. Gonen M, Hellar G. Concordance probability and discriminary power in proportional hazards regression. Biometrika 2005;92:965-70. (Pubitemid 41681247)
21. Curtis JR, Jain A, Askling J, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010;40:2-14.e1.
22. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12. (Pubitemid 41612206)
23. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44. (Pubitemid 47492478)
24. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
25. Manno R, Calabrese L, Curtis J, et al. Evaluating immunization knowledge and practices by rheumatologists. Arthritis Rheum 2008;58:4007.
26. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
27. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther 2008;10:R95.